Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€28.50

€28.50

-4.900%
-1.48
-4.900%
€59.00
 
21:04 / Tradegate WKN: A3ENQ5 / Name: Schott Pharma & Co. Kgaa / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Schott Pharma AG & Co. Kgaa Stock

Schott Pharma AG & Co. Kgaa took a tumble today and lost -€1.480 (-4.900%).
The community is currently still undecided about Schott Pharma AG & Co. Kgaa with 2 Buy predictions and 0 Sell predictions.
With a target price of 59 € there is potential for a 107.02% increase which would mean more than doubling the current price of 28.5 € for Schott Pharma AG & Co. Kgaa.

Pros and Cons of Schott Pharma AG & Co. Kgaa in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
EQS-News: SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
EQS-News: SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes
EQS-News: SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations
EQS-News: SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations
EQS-News: SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations